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Abstract
Background: Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) has been 
adopted as policy by most countries in sub-Saharan Africa. This cross-sectional study assessed the prevalence of  IPTp-SP 
usage for prevention of  malaria among pregnant women as well as evaluated factors associated with IPTp-SP use during 
pregnancy in Sekondi-Takoradi region of  Ghana.
Methods: Pregnant women attending their antenatal-care with either clinical/ultrasound evidence of  pregnancy were re-
cruited. Venous blood was screened for malaria using RAPID response antibody kit and Giemsa staining. Haemoglobin esti-
mations were done by cyanmethemoglobin method while Human Immunodeficiency Virus (HIV) screening was performed 
by the national diagnostic algorithm of  two rapid antibody test and western blot confirmation. 
Results: Of  the 754 consented pregnant women interviewed in this study, 57.8% had received IPTp-SP while 42.2% had 
not at their first contact with the study personnel. Furthermore, 18.6% (81/436) of  those that received IPTp-SP were ma-
laria positive while 81.4% (355/436) were malaria negative. The results also indicated that 47.7% (51/107) of  the pregnant 
women in their third trimester who were meant to have received at least two-doses of  SP had received ≥2 doses while 35.5% 
(38/107) had received 1 dose. In multivariable logistic regression analysis, pregnant women in their third trimester who re-
ceived ≥2 doses of  SP showed decreased likelihoods of  malaria (adjusted OR, 0.042; 95% CI, 0.003-0.51; P = 0.013). 
Conclusion: IPTp-SP usage among pregnant women in Sekondi-Takoradi reduces malaria and its use for malaria prevention 
should be strengthened with proper dosage completion and coverage.
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Introduction
Malaria in pregnancy is an immense public health chal-
lenge, affecting about 50 million women per year, caus-
ing maternal, foetal and infant morbidity and mortal-
ity especially in sub-Saharan Africa1. Approximately 
25 million pregnant women are at risk of Plasmodium 
falciparum infection which is the protozoan parasite that 
causes malaria in sub-Saharan Africa1. Among pregnant 
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women in Ghana, malaria accounts for about 13.8% 
of  outpatient attendance and about 11% of  maternal 
mortality. It is the leading cause of  illness and death in 
the country impacting negatively on different socio-de-
mographic groups2. The consequences of  P. falciparum 
infection in pregnancy consist of  maternal anaemia, 
low birth weight, preterm delivery, prenatal mortality, 
abortion, still birth, intrauterine growth retardation and 
even maternal mortality in some cases1,3-5. The severity 
of  the adverse effects of  malaria in pregnancy depends 
on gravidity and maternal age. However, primigravidae 
are at greater risk of  malaria and its adverse effects than 
multigravidae and non-pregnant women from the same 
area6. 
World Health Organization (WHO) recommends the 
use of  intermittent preventive treatment during preg-
nancy (IPTp) with sulphadoxine and pyrimethamine 
(SP), given at least twice at scheduled antenatal visits 
after quickening7.Ghana started this implementation in 
2004 and the prevalence of  placental malaria and ma-
ternal anaemia reduced substantially following the im-
plementation of  IPTp-SP8. The key goal of  the global 
action plan is to cover 80% of  the  pregnant women 
in malaria endemic regions receiving no less than two 
doses of  IPTp-SP in order to reduce the complica-
tions that arise from malaria in pregnancy9,10. The 2011 
multiple indicator cluster survey from Ghana indicated 
progress on IPTp in Ghana although this has not been 
sustained11. IPTp-SP administered to  pregnant women 
in their second and third trimesters has been observed 
to reduce the risk of  malaria12,13, placental malaria8, low 
birth weight and preterm births12-14, and maternal anae-
mia13,15. SP has a good safety profile16, and is cheap, cost 
effective and easy to administer through the already ex-
isting antenatal-care clinics (ANC)10,17. 
Anaemia during pregnancy is a major global health 
problem, affecting nearly half  of  all pregnant women 
globally18. While the risk of  anaemia in pregnancy in-
creases with pregnancy progression18, the aetiology of  
anaemia in pregnancy is multifaceted ranging from un-
dernourishment, iron deficiency, vitamins A and B12 de-
ficiency, folate deficiency, sickle cell anaemia, thalassem-
ia, Human Immunodeficiency Virus (HIV) infection, 
malaria and other parasites such as hookworm, Ascaris 
and Schistosoma19-23. However, in sub-Saharan Africa, 
malaria is a major contributor of  anaemia22. Recently, 
studies showed that the influence of  timing and fre-
quency of  P. falciparum malaria infection in late pregnan-
cy were related to higher risk of  maternal anaemia and 
low birth weight24,25. Although HIV infected pregnant 
women experience more malaria, dually infected preg-
nant women are more likely to have febrile illnesses26 
and anaemia than women with either malaria or HIV 
single infection26,27.
While there are overwhelming support and evidence 
that IPTp-SP helps to reduce the risk of  malaria when 
full doses are administered8,12-15,28-30, meeting the key 
goal coverage of  80% of  the pregnant women receiving 
at least two doses of  SP has been an uphill task31. We 
therefore conducted this cross-sectional study first to 
examine the prevalence of  IPTp-SP usage for malaria 
prevention among pregnant women in Sekondi-Tako-
radi, secondly to evaluate the impact of  IPTp-SP use 
on malaria prevalence among pregnant women in their 
third trimester meant to have received at least 2 dos-
es of  SP according to the WHO criteria7 and lastly, to 
study other factors associated with malaria among the 
pregnant women in the sub-region.
 
Materials and methods
Study area and population
This study was conducted at four hospitals in the Se-
kondi-Takoradi metropolis namely Effia Nkwanta Re-
gional Hospital (the referral hospital in the region), 
Takoradi and Esikado Hospitals (Government hospi-
tals) and Jemima Hospital (a private hospital). Details of  
the study population have been published elsewhere32. 
The hospitals are strategically located and were selected 
based on the size of  attendance of  pregnant women 
that come for their monthly ANC. Sekondi-Takora-
di, the administrative capital of  the western region of  
Ghana, is an industrial and commercial centre with a 
population of  about 335,000 and a land area of  385 
square kilometres. It is located about 242 kilometers to 
the West of  Accra, the capital city and approximately 
280 kilometers from the Côte d'Ivoire border.  In this 
area, pregnant women (representing 4% of  the popu-
lation) are highly vulnerable to malaria infection2. The 
other highly vulnerable population are children under 
five years that constitute about 20% of  the population. 
 
Recruitment of  the pregnant women
A cross-sectional study was carried out between March 
and October, 2010 at the earlier mentioned hospitals. 
Pregnant women attending their ANC visits with either 
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clinical or ultrasound evidence of  pregnancy were in-
cluded in this study while those with severe bleeding 
were excluded from this study. Each facility was visit-
ed once every week on their routine antenatal days and 
all interviewed pregnant women were given adequate 
clinical attention and care by the respective hospitals. 
All consented pregnant women were recruited through 
the convenient sampling method, and were interviewed 
once (first contact with our study personnel) and their 
subsequent ANC visitations were not included in the 
data analysis. Interviews took place before their primary 
care consultations and pregnant women who received 
SP doses at their first contact with the study personnel 
were excluded from the data analysis. Written informed 
consents were obtained from all pregnant women that 
participated in this study. Ethical clearance was received 




A total of  seven hundred and seventy six (776) pregnant 
women were interviewed out of  which 754 gave their 
consent and were included in the data analysis. Infor-
mation was obtained using a standardized questionnaire 
in English language interpreted in the patients’ local 
language during the interviews. Two registered nurses 
who speak the same dialect translated the questionnaire 
information to the local language. Information on their 
socio-demographic characteristics, past and present ob-
stetrics history, gravidae status, age, education, occupa-
tion, IPTp-SP use and other information were record-
ed. The numbers of  SP doses taken by the pregnant 
women were documented on their ANC cards. Histo-
ry of  fever and any other illness during the pregnancy 
were documented.
HIV screening for the pregnant women was performed 
and statuses of  the women were obtained from the 
prevention of  mother-to-child transmission (PMTC) 
clinic in the hospitals. Sero-statuses were determined by 
applying the national diagnostic algorithm of  two rap-
id antibody tests and western blot confirmation while 
indeterminate cases were confirmed at the reference 
laboratory of  the Regional Hospital. Five mls of  ve-
nous blood was collected from the pregnant women by 
a trained laboratory technician from the median cubi-
tal vein. Blood samples were collected into an EDTA 
bottle and temporarily stored in an ice chest and were 
transported to a designated reference laboratory for 
same day analysis and storage. 
Laboratory diagnosis of  malaria was performed using 
fast RAPID response antibody kit (Premier Medical 
Corporation Ltd, Daman, India) and Giemsa staining. 
The brand of  the RAPID response kit was specific for 
the detection of P. falciparum antigens. The presence of  
two lines in the test kit well indicated positive for P. 
falciparum malaria. For proper confirmation of  malar-
ia parasites, thick and thin films stained with Giemsa 
were prepared immediately upon blood collection on 
the same slide and examined microscopically using 100 
power fields under oil immersion. The stained slides 
were read by 2 competent independent microscopists 
and where they had discordances, a third microscopist 
reassessed the slide. Haemoglobin estimation was per-
formed using cyanmethemoglobin method33. Anaemia 
was defined based on WHO criteria haemoglobin lev-
els of  <11 g/dL34. Schistosoma haematobium was detected 
from wet mount preparation examination using micros-
copy of  the concentrated sediments in urine. All labo-
ratory personnel were blinded to the status of  patients. 
 
Statistical analysis
Socio-demographic characteristics of  the pregnant 
women were based on Pearson's chi-squared test (χ2) or 
exact chi-square for categorical variable and ANOVA 
for the comparison of  the mean of  the continuous var-
iables. Age was dichotomized as adolescence and adults 
while the latter was used as the reference. Gravidity was 
categorized as primigravidae, secundigravidae and mul-
tigravidae using multigravidae as the reference in the 
logistic regression analysis. The number of  SP doses re-
ceived during pregnancy (0, 1 and ≥2) were categorized 
and no SP doses (0) was used as the reference in the 
logistic regression models. Multivariable logistic regres-
sion analyses were used to assess the factors associated 
with malaria among the pregnant women controlling 
for age, gestation, gravidae, education, occupation, S. 
haematobium infection, fever, IPTp-SP use and HIV 
infection. Due to the multifactorial aetiology of  anae-
mia in pregnancy, age, gravidae, occupation, education, 
IPTp-SP use, S. haematobium, fever, HIV and malaria in-
fections were as well treated as covariates in the logistic 
regression models. Confounding was considered based 
on the results of  univariable analysis, biological plausi-
bility and, in addition, a +/- 10% change in odds ratio 
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(OR) estimate. To assess the probable effect of  IPTp-
SP use in the sub-region, pregnant women in their third 
trimester (who were expected to have received at least 
2 doses of  SP according to the WHO criteria7) were 
selected for further analysis using no SP doses as the 
indicator in the logistic regression model. All tests were 
two-tailed and P value of  0.05 or less was considered as 
statistically significant. The OR and 95% confidence in-
terval (CI) were used to measure the strength of  the as-
sociations. All statistical analyses were performed with 
IBM SPSS Statistics version 21.0 (IBM Corporation, 
Armonk, NY, USA).
Results
Characteristics of  the study participants
Table 1 describes the general characteristics and ob-
stetric history of  the study population. Of  the 754 
consented pregnant women interviewed in this study, 
57.8% had received IPTp-SP while 42.2% had not re-
ceived IPTp-SP at their first contact with the study per-
sonnel. The mean (± SD) age of  the pregnant women 
was 26.17 ± 5.5 years. There were no statistically sig-
nificant differences in the mean age of  the pregnant 
women who received IPTp-SP (26.3 ± 5.6) and those 
who had not received IPTp-SP (25.7 ± 5.4) [Table 1]. 
Table 1 
Characteristics and obstetric history of the pregnant women during their antenatal care 
visitation. 
  
Socio-demographic    No IPTp-SP   IPTp-SP use  P 
characteristics    (n = 318)   (n = 436)                            value 
  
Age (years)      
      Mean ± SD                    25.7 ± 5.4  26.3 ± 5.6  0.11 
      ≤19                     13.8     12.1 
      20-29      62.6   59.4   0.13 
      30-39      23.3   26.4 
      >40                     0.3      2.1 
Education 
      None      22.0    19.5    
      Primary      11.3   16.0   0.15 
      Secondary      60.7   61.5 
      Tertiary      6.0    3.0 
Occupation 
      Civil service                    2.2      2.1 
      Farmer/Trader/Caterer/Fishing                  94.2   96.6   0.27 
      Teacher/Student     3.6       1.3 
Gravidae 
      Primigravidae                  62.9   55.4 
      Secundigravidae    28.3   35.5   0.11 
      Multigravidae      8.8      9.1 
Trimesters 
      1st trimester                  38.9       0   
      2nd trimester                  55.4   77.8   <0.001 
      3rd trimester                  5.7    22.2 
Maternal anaemia 
      <11 g/dL    31.8   36.2   0.22 
      >11 g/dL    68.2                                63.8 
Malaria status 
      Negative    63.5   81.4   <0.001 
      Positive    36.5     18.6 
HIV status 
      Negative    86.2   90.1   0.092 
      Positive    13.8      9.9 
Febrile (fever) 
      Yes                   41.0   26.6   <0.001 
      No      59.0   73.4 
Admission 
      Yes                   1.6    2.5   0.37 
      No      98.4   97.5 
Schistosoma haematobium 
      Negative    85.5   88.9   0.17 
      Positive    14.5     11.1 
Malaria co-infection with S. haematobium 
      Negative    84.5   90.1   0.29 
      Positive     15.5       9.9 
NB: N = number of samples. SD = standard deviation. IPTp-SP = intermittent preventive treatment with sulfadoxine-
pyrimethamine. Dataare percentages of the pregnant women. 
P values were based on Pearson chi-squared test or exact chi-square for categorical variables and ANOVA for the 
comparison of the mean of the continuous variables.  
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There were also no statistically significant differences 
with education, occupation, gravidae, anaemia and HIV 
status of  the pregnant women who received IPTp-SP 
and those who have not in univariable analysis. How-
ever, the proportion of  pregnant women who received 
IPTp-SP and those who had not received IPTp-SP at 
their first contact with the study personnel differed with 
trimester, febrile and malaria status.
IPTp-SP, SP doses and the prevalence of  malaria
Thick and thin smears were used to detect malaria par-
asites from all the 754 recruited pregnant women. More 
than half  of  the pregnant women were malaria negative 
73.9% (557) while 26.1% (197) were infected with ma-
laria parasites. Among those that were infected with ma-
laria parasites, 18.6% (81/436) received IPTp-SP while 
36.5% (116/318) had not received IPTp-SP (Table 1). 
In addition, when stratified by the number of  SP doses 
received, 20.7% of  women who received one SP dose 
were malaria infected while 13.7% who received two 
doses of  SP were malaria infected (Table 2). The re-
sults also indicated that the majority 86.3% (113/131) 
of  the pregnant women who had received ≥2 doses of  
SP were malaria negative (Table 2). 
Table 2 
Malaria statuses of the pregnant women by the number of SP doses. 
  
Malaria status                       SP doses                  
     ______________________________________   
    0       1   ≥2                    P value  
    n = 318 (%)     n =305 (%)  n =131 (%)   
Malaria negative  202 (63.5)     242 (79.3)  113 (86.3)        <0.001 
Malaria positive  116 (36.5)       63 (20.7)      18 (13.7)  
P value derived from Pearson Chi-Square test. n = number of pregnant women. SP = sulphadoxine-pyrimethamine. 
IPTp-SP and haemoglobin levels
Haemoglobin levels (g/dL) did not differ among those 
who received IPTp-SP and those who have not re-
ceived. However, when those that received IPTp were 
selected for further analysis, pregnant women who re-
ceived 3 doses of  SP had higher median haemoglobin 
levels as compared with other doses though it did not 
reach statistical significance. No statistical significance 
was also observed with pairwise multiple comparisons 
of  0, 1 and 2 doses with 3 doses. 
 
Risk factors associated with malaria among the 
pregnant women
A separate model was run to assess the effect of  factors 
associated with malaria infection among the recruited 
pregnant women. The possible confounding effects 
of  age, adolescence, gravidae, gestational age, occupa-
tion, education and other variables were controlled us-
ing multivariable logistic regression analysis. The data 
showed that pregnant women with tertiary education 
had reduced odds of  malaria infection (adjusted OR, 
0.39; 95% CI, 0.15-0.99; P = 0.021) [Table 3]. Howev-
er, HIV co-infection increased the odds of  malaria in 
pregnancy by two-fold (adjusted OR, 2.37; 95 % CI, 
1.35-4.16; P = 0.003). Similarly, women who were anae-
mic were two times more likely to have malaria when 
compared to women who were not anaemic (adjusted 
OR, 1.98; 95 % CI, 1.28-3.06; P = 0.002). In a sepa-
rate model to explore the association between IPTp-SP 
use and malaria infection in the study population, 1 or 
≥2 SP doses was associated with preventing malaria in 
pregnancy. But, after regression assumption, confound-
ing and interaction in multivariable logistic regression 
analysis, decreased odds of  malaria was strongly associ-
ated with only ≥2 doses of  SP (adjusted OR, 0.41; 95% 
CI, 0.19-0.88; P = 0.023) [Table 3].
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Table 3  
Multivariable logistic regression analyses of factors associated with malaria among the pregnant women. 
 
 
Variables   n  Unadjusted OR (95% CI)  *Adjusted OR (95% CI) P value 
  
 
Age (years)    
    ≤19      97  1.95 (1.26-3.01)   0.96 (0.91-1.02)  0.15 
    ≥20    657  1     1 
Gravidae 
    Primigravidae  441  0.72 (0.43-1.21)   0.54 (0.24-1.24)  0.14 
    Secundigravidae  245  0.50 (0.28-0.89)   0.54 (0.26-1.12)  0.097 
    Multigravidae     68  1     1 
Education 
    None   155  1     1 
    Primary   106  0.98 (0.58-1.66)   1.34 (0.67-2.67)  0.41 
    Secondary   461  0.76 (0.51-1.13)   0.90 (0.52-1.54)  0.69 
    Tertiary      32  0.58 (0.23-1.50)   0.39 (0.15-0.99)  0.021 
Schistosoma haematobium  
    Negative   659  1     1 
    Positive      95  0.92 (0.57-1.47)   0.95 (0.52-1.75)  0.88 
HIV 
    Negative   667  1     1 
    Positive     87  4.31 (2.73-6.79)   2.37 (1.35-4.16)  0.003 
Maternal anaemia 
    No    495  1     1 
    Yes    259  2.05 (1.48-2.82)   1.98 (1.28-3.06)  0.002 
IPTp-SP use 
    0    318  1     1 
    1    305  0.45 (0.32-0.65)   0.69 (0.42-1.11)  0.13 
    ≥2    131  0.28 (0.16-0.48)   0.41 (0.19-0.88)  0.023 
NB: OR = odds ratio. CI = confidence interval. 
*Adjusted ORs are derived from multivariable binary logistic regression, controlling for age, adolescent, gestation, gravidae, education, occupation, febrile (fever), IPTp-SP 
use and HIV status. P < 0.05 was considered statistical significance.  
(51/107) received ≥2 doses of  SP and 35.5% (38/107) 
received only 1 dose while 16.8% (18/107) received no 
SP doses [Table 4]. The data also indicated that 84.3% 
(43/51) of  those that received ≥2 doses of  SP were ma-
laria negative while 15.7% (8/51) were malaria positive. 
In multivariable modelling, receipt of  ≥2 SP doses was 
statistically significantly associated with reduced risk of  
malaria infection (adjusted OR, 0.042; 95% CI, 0.003-
0.51; P = 0.013) [Table 4].
IPTp-SP use in third trimester  
To evaluate the impact of  SP doses on malaria preva-
lence in the sub-region, only pregnant women in their 
third trimester, who were supposed to have received 
at least 2 doses of  SP by the WHO recommendation, 
were selected for further analysis. The result indicat-
ed that 83.2% (89/107) of  the pregnant women in 
their third trimester received SP. Out of  these, 47.7% 
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Discussion
In this study, our results showed that pregnant women 
who received ≥2 doses of  SP during their third trimes-
ter had significantly decreased likelihoods of  malaria. 
This observation is analogous with previous data from 
different malaria regions of  sub-Saharan Africa8,12-14. 
The data also showed that the majority of  the recruit-
ed pregnant women (81.4%) who received IPTp-SP 
were malaria negative. However, 15.7% of  the preg-
nant women in their third trimester that had received 
≥2 doses of  SP were malaria positive. This observation 
could be as a result of  possible re-infection or probably 
by the increase of  SP drug resistance in pregnant wom-
en in Ghana since the adoption and implementation of  
IPTp-SP policy35. Furthermore, the number of  doses 
given to pregnant women could be an important factor 
in IPTp-SP usage36 as there were significant differences 
in malaria prevalence with regard to the number of  SP 
doses received by the pregnant women.
IPTp-SP is believed to be tolerable in pregnancy with 
no evidence of  teratogenicity once given during the 
second and third trimesters16. However, despite the effi-
cacy and cost effectiveness of  IPTp-SP, SP drug resist-
ance have been reported in Ghana35,37, as seen in most 
part of  sub-Saharan Africa38 and debate over its safety 
and efficacy continues39-41. IPTp-SP had been shown to 
reduce the risk of  anaemia especially in pregnant wom-
en15. In our cross-sectional study, we found no haemo-
globin levels differences between those who received 
IPTp-SP and those who had not received IPTp-SP 
during the study period. This discrepancy could be as 
a result of  study design differences. The earlier study 
utilised a smaller sample size (363) which may have had 
decreased precision when estimating unknown param-
eters while our cross-sectional study utilised a higher 
sample size (754). However, the haemoglobin levels of  
pregnant women who received 3 doses of  SP tended to 
be higher than those with 1-2 doses though it was not 
statistically significant. 
The attainment of  80% coverage of  pregnant women 
in malaria endemic region, like in Ghana, receiving at 
least two doses of  IPTp-SP remains an uphill task. In 
a previous study, early ANC attendance, highly moti-
vated personnel and compliance by pregnant women 
favoured the completion of  IPTp42. But, earlier data 
from Uganda indicated that ANC visits do not actually 
ensure access to IPTp-SP in the presence of  other bar-
riers like stock-outs, long distance, irregular ANC vis-
its or late ANC attendance43. In our study population, 
47.7% of  the pregnant women in their third trimester 
who were meant to have received ≥2 doses of  SP had 
completed the dosage. The reason for this low cover-
age with IPTp-SP could be related to late attendance 
to ANC, lack of  completion of  ANC visits and weak 
health services44. The lack or inconsistency in prenatal 
service attendance in some communities indicates that 
some pregnant women will not have access to IPTp-SP, 
some who have end up with less than the required dos-
es before the delivery of  the baby. This might still pre-
dispose them to anaemia and low birth weight of  the 
baby. Three doses of  IPTp-SP have been found to be 
more effective in malaria prevention than two doses as 
it halved the risk of  placental malaria, low birth weight 
and preterm delivery14. Recently, a systematic review and 
meta-analysis suggested a new recommendation to pro-
vide at least 3 doses of  SP especially during the second 
and third trimester45. It is imperative that measures like 
focused antenatal care and social mobilization be imple-
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Table 4  
The effect of IPTp-SP use on the pregnant women during their third trimester. 
 
SP doses  Malaria status   Unadjusted OR (95% CI)  Adjusted OR (95% CI) P value 
(n = 107)  __________________ 
   Negative Positive 
  
0 (18)   11 (61.1) 7 (38.9) 1     1 
1 (38)   30 (78.9) 8 (21.1) 0.42 (0.12-1.43)   0.11 (0.14-0.83)  0.032 
≥2 (51)  43 (84.3) 8 (15.7) 0.29 (0.087-0.98)   0.042 (0.003-0.51)  0.013 
 
Adjusted ORs are derived from multivariable logistic regression analysis, controlling for age, gestation, gravidae, febrile, HIV and occupation. 
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mented to increase the proportion of  pregnant women 
who take ≥2 doses of  SP in this sub-region. Further-
more, targeted education to women of  child-bearing 
age needs more emphasis as studies have revealed the 
influential impact on malaria control46,47. This was evi-
denced in our study as pregnant women pregnant with 
tertiary education had reduced risk of  malaria infection.
Limitations
There are few limitations to this study. First, none meas-
urement of  pregnancy outcomes like low birth weight 
and placental malaria, which are evidence of  the asso-
ciation of  malaria in pregnancy. Secondly, the use of  
insecticides treated mosquito bed nets was not included 
and this was not a randomized controlled clinical trial. 
This cross-sectional study allowed for a single encoun-
ter with the pregnant women and not all the pregnant 
women had an equal chance to receive IPTp. In addi-
tion, none measurement of  other likelihood cause of  
anaemia also limited our analysis and none was followed 
till delivery. In view of  the said, the interpretation of  
results should be based with reference to the observed. 
It would be ideal to conduct a controlled longitudinal 
study assessing the impact and effectiveness of  IPTp 
use in the region and the potential factors involved in 
the selection of  SP drug resistance.
Conclusion
This work further buttresses the importance of  IPTp-
SP usage among pregnant women in preventing malaria 
and also shows the importance of  dosage completion. 
Additional studies are recommended to assess the ef-
fectiveness of  IPTp-SP use in a more detailed design 
that will measure low birth weight, placental malaria, 
the effects of  insecticides treated mosquito bed nets 
and the drifts of  SP drug resistance in the region. This 
is very essential in the wake of  IPTp-SP drug resistance 
being reported by many workers.
 
Presentation of  results
This result was presented in part at the 61st Annu-
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